- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01360996
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (BEYAZ-PCOS)
Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70815
- Woman's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
•Adult female-16 years to 35 years of age who have been diagnosed with PCOS desiring contraception
- Actual BMI >18 to <35kg/ m2
- Written consent for participation in the study
- Patient completed lactation
Exclusion Criteria:
Metabolic abnormalities requiring pharmacological intervention (except controlled thyroid disease)
- Uncontrolled hypertension
- Cancer or history of hormone-dependent cancer
- History of cholestasis
- Presence of contradictions for OC administration
- Personal history of cardiovascular events.
- Use of drugs known to exacerbate glucose tolerance.
- No prescription or over-the-counter weight-loss drugs
- Diabetes
- Use of medications that affect blood pressure or lipid profile
- Smoking in past 6 months
- Known thrombogenic mutations (e.g. Factor V Leiden)
- Current or history of deep venous thrombosis/pulmonary embolism
- Major surgery with prolonged immobilization
- Injectable hormonal contraceptive use within 6 months
- Use of hormonal (e.g., oral contraceptive [OC] pill) or insulin-sensitizing medication unless willing to cease medications for 3 months before study measurements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 3 mg DRSP/20 μg EE--normal weight
Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive Normal weight -BMI 18-24.9 kg/ m2 |
1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Other Names:
|
EXPERIMENTAL: 3 mg DRSP/20 μg EE- Overweight
Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive BMI 25-29.9 kg/ m2 |
1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Other Names:
|
EXPERIMENTAL: 3 mg DRSP/20 μg EE- Grade 1 obese
Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive BMI 30-34.9 kg/ m2 |
1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical Assessment of Hyperandrogenism
Time Frame: 24 weeks
|
The primary outcome measure is post-treatment Free Androgen Index(FAI) which is expressed in units. FAI is calculated by taking the testosterone concentration (in nmol/l) and dividing by concentration of sex hormone binding globulin (SHBG in nmol/L)and multiplying by 100 |
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiometabolic Measures
Time Frame: 24 weeks
|
Values represent blood pressure at 24 weeks.
|
24 weeks
|
Post Therapy BMI.
Time Frame: 24 weeks
|
Post-treatment body mass index at 24 weeks
|
24 weeks
|
Biochemical Indicator of B-vitamin Status
Time Frame: 24 weeks
|
Post-treatment in folate concentrations after 24 weeks of treatment
|
24 weeks
|
Menstrual Cycle Regularity
Time Frame: 24 weeks
|
Post treatment menstrual frequency over 24 weeks normalized to number of menses per year ..
|
24 weeks
|
Adrenal Androgen DHEAS
Time Frame: 24 weeks
|
Post-treatment levels of adrenal androgen DHEAS
|
24 weeks
|
Oral Disposition Index
Time Frame: 24 weeks
|
Post-treatment insulin secretion-sensitivity index (ISSI) calculated from the oral glucose tolerance test (OGTT).
A higher value indicate improved carbohydrate metabolism
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karen E Elkind-Hirsch, M.Sc.,Ph.D., Woman's Hospital, Louisiana
- Principal Investigator: Martha Paterson, M.D., Woman's Hospital Metabolic Health Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- 46, XX Disorders of Sex Development
- Disorders of Sex Development
- Urogenital Abnormalities
- Adrenogenital Syndrome
- Congenital Abnormalities
- Polycystic Ovary Syndrome
- Hyperandrogenism
- Syndrome
- Physiological Effects of Drugs
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptive Agents
- Contraceptives, Oral
Other Study ID Numbers
- RP 11-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovary Syndrome
-
Cairo UniversityCompleted
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
Assaf-Harofeh Medical CenterUnknownInfertility | Polycystic OvariesIsrael
-
Fundació Sant Joan de DéuRecruitingPolycystic Ovary Syndrome (PCOS)Norway, Austria, Denmark, Italy, Spain, Turkey
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedPolycystic Ovary Syndrome (PCOS)United States
-
University Magna GraeciaCompletedInfertility | Polycystic Ovary Syndrome (PCOS)Italy
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark
Clinical Trials on 3 mg DRSP/20 μg EE
-
BayerCompleted
-
BayerCompletedAcne VulgarisUnited States
-
EstetraCompletedContraception | Liver Metabolism | Hemostasis ParameterNetherlands
-
BayerCompleted
-
Organon and CoCompleted
-
BayerCompleted